Industry News
Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Phase IIb adaptive trial planning to enroll 100 patients Second Phase IIb study of vafidemstat in CNS disorders Excerpt from the Press Release: MADRID, Spain and CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code:…
Read More
Excerpt from the Press Release: Every day, hundreds of thousands of new COVID-19 cases and thousands of new deaths are still being reported worldwide, creating a need for drugs that can combat the disease caused by SARS-CoV-2. Now, new research led by investigators at Harvard Medical School and Boston Children’s Hospital points to a well-known…
Read More
Submission based on Phase 2/3 study of SPIKEVAX in children ages 6 to 11 Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for authorization with Health Canada for the evaluation of a 50 µg two-dose series…
Read More
Seventeen objective responses reported across nine cancers Evidence of monotherapy activity, with four cases of confirmed objective response Objective responses noted in treatment refractory, poorly immunogenic tumors including microsatellite stable (MSS) colorectal cancer, ovarian cancer, MSS endometrial cancer, and melanoma; as well as responses in tumors not previously reported including pancreatic cancer, cervical cancer, visceral…
Read More
Excerpt from the Press Release: We are pleased that The Lancet, a trusted source of clinical, public health and global health knowledge, published Phase 3 data showing the COVID-19 vaccine candidate, COVAXIN™ (BBV152), has 93.4% efficacy against severe COVID-19 disease. COVAXIN™ (BBV152), a whole virion inactivated COVID-19 vaccine candidate, uses the same technology that is safely and effectively applied in the production of Bharat…
Read More
New, Single-arm Phase 3 Study Expected to Initiate in Early 2022 Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, is announcing at its virtual Spotlight Event being held today that, following recent discussions with the…
Read More
— Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK) cell therapies with enhanced anti-tumor function — — Lead product candidate WU-NK-101 demonstrated potent anti-tumor activity and long-term persistence in vivo — — Data support ongoing clinical development of WU-NK-101 as best-in-class memory NK…
Read More
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR and Bruton’s tyrosine kinase (BTK) in advanced NSCLC patients resistant to first-line EGFR kinase inhibitor therapies. In this pivotal study conducted in China, 227 heavily pretreated NSCLC patients were enrolled and among 209 response evaluable patients, confirmed overall…
Read More
Excerpt from the Press Release: Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today reported in vitro and in vivo preclinical…
Read More
Initial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Excerpt from the Press Release: Initial clinical…
Read More